Delivery Order SPE2DB22D3301-SPE2DB25FY9CU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract valued at approximately $12.0K. This award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled from the contractor's facility in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026 that provides comprehensive pharmaceutical and...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $28,416.82 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, reflecting the company's proven capability to...
- The Defense Logistics Agency awarded a $16,470.89 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (quantity: 30 units) on September 19, 2025, with completion targeted for September 22, 2025. The award, which carries no set-aside designation, represents a competitive delivery order against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for RINVOQ ER 15 mg tablets (30-count units) with a ceiling value of $5,399.73. This is a firm fixed price delivery order with no set-aside designation, executed as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $5,846.07 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 21, 2025, with a completion date of August 22, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, to be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $25,189.80 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation and...
- The Defense Logistics Agency awarded a $50,518.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 20, 2025, with an ultimate completion date of June 23, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a $4,097.72 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) with an ultimate completion date of May 28, 2025. This non-set-aside, firm fixed price contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY9CUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $74,493.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (quantity: 30s) on August 8, 2025, with completion targeted for August 11, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle extending through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order supports the Defense Health Agency and broader military healthcare operations through AmerisourceBergen's role as a major federal pharmaceutical distributor. RINVOQ (upadacitinib), a prescription medication for inflammatory conditions, represents the type of specialty pharmaceutical product the company routinely supplies through its comprehensive DLA contract portfolio. As a prime vendor under the DLA's global pharmaceutical support program, AmerisourceBergen provides an extensive range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare systems worldwide, demonstrating the company's established capability to fulfill federal medical procurement requirements across multiple therapeutic domains.